Literature DB >> 9527161

Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.

J N Lycke1, J E Karlsson, O Andersen, L E Rosengren.   

Abstract

The neurofilament protein is a major structural protein of neurons and a marker for axonal damage. The concentrations of the light subunit of the neurofilament triplet protein (NFL) in CSF were significantly increased in patients with relapsing-remitting multiple sclerosis compared with healthy controls (p<0.001). Seventy eight per cent of patients with multiple sclerosis showed increased NFL concentrations. Significant correlations between the NFL concentration in CSF and clinical indices were discerned for disability, exacerbation rate, and time from the start of the previous exacerbation to the time of the lumbar puncture. The results suggest that axonal damage occurs during relapsing-remitting multiple sclerosis and that the damage contributes to disability and the appearance of clinical exacerbations. The concentration of NFL in CSF is a potential marker of disease activity in multiple sclerosis and might be useful in future clinical trials of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9527161      PMCID: PMC2170011          DOI: 10.1136/jnnp.64.3.402

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  70 in total

1.  Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis.

Authors:  Ales Bartos; Lenka Fialová; Jirina Soukupová; Jaromír Kukal; Ivan Malbohan; Jirí Pit'ha
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

Review 2.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

Review 3.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

4.  Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis.

Authors:  Roberto Madeddu; Cristiano Farace; Paola Tolu; Giuliana Solinas; Yolande Asara; Maria Alessandra Sotgiu; Lucia Gemma Delogu; Jose Carlos Prados; Stefano Sotgiu; Andrea Montella
Journal:  Neurol Sci       Date:  2012-02-24       Impact factor: 3.307

Review 5.  MRI and multiple sclerosis-the evolving role of MRI in the diagnosis and management of MS: a clinician's perspective.

Authors:  H Kearney; A M Cahalane; R P Killeen; C McGuigan
Journal:  Ir J Med Sci       Date:  2017-10-10       Impact factor: 1.568

6.  Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

Authors:  A Petzold; M J Eikelenboom; G Keir; D Grant; R H C Lazeron; C H Polman; B M J Uitdehaag; E J Thompson; G Giovannoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

7.  Cerebrospinal fluid in multiple sclerosis.

Authors:  Kottil W Rammohan
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

Review 8.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

9.  Detection of glial fibrillary acidic protein and neurofilaments in the cerebrospinal fluid of patients with neurocysticercosis.

Authors:  J Luis Quintanar; Luis Manuel Franco; Eva Salinas
Journal:  Parasitol Res       Date:  2003-03-12       Impact factor: 2.289

Review 10.  Neurofilaments in disease: what do we know?

Authors:  Brian A Gordon
Journal:  Curr Opin Neurobiol       Date:  2020-03-06       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.